Stock Market & Financial Investment News

FDA says Exact Sciences colorectal cancer screening tool study met objectivesExact Sciences' Deep-C study met the primary objectives with respect to both required sensitivity and specificity of the company's Cologuard test compared to colonoscopy, FDA staff wrote in briefing documents ahead of the March 27 meeting of the Molecular and Clinical Advisory Committee Panel. With respect to the secondary objectives, Cologuard sensitivity is higher than FIT for both CRC and AA, FDA staff noted. Cologuard is an in vitro diagnostic device designed to analyze patientsí stool for the presence of colorectal cancer. Reference Link

Exact Sciences files to sell 7M shares of common stockThe Company intends to use the net proceeds of this offering to fund expansion of Cologuard commercialization activities, to fund product development efforts, and for general corporate and working capital purposes. Jefferies LLC and Robert W. Baird & Co. Incorporated are acting as the underwriters for the offering.